Charles River Laboratories International experienced notable upward momentum driven by a combination of positive industry-wide sector rotation, favorable analyst sentiment, and strong operational updates following its strategic Investor Day. Broad buying across preclinical research and contract research organizations provided strong tailwinds, as institutional investors rotated capital back into life sciences services amid signs of stabilizing biopharmaceutical research and development expenditures.

A major driver behind the stock’s performance is management’s updated financial outlook and long-term strategic vision. During its Investor Day presentation, the company signaled that full-year earnings and revenue are expected to reach the…